References
- McKelvey EM, Gottlieb JA, Wilson HE, et al Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484–1493.
- Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Schubert J, Ziepert M, et al for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
- Schulz H, Bohlius JF, Trelle S, et al Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
- Vellenga E, van Putten WL, van't Veer MB, et al Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537–543.
- Dreyling M, Forstpointner R, Boeck H, et al Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma. Blood 2006;108(Suppl. 1):784a (Abstract 2769).
- Gisselbrecht C, Glass B, Mounier N, et al R-ICE vs. R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009;27(Suppl.):793s (Abstract 8509).
- Martin A, Conde E, Arnan M, et al R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829–1836.
- Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, et al Retreatment with rituximab in 178 patients with elapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma 2010;51:401–407.
- Dunleavy K, Pittaluga S, Czuczman MS, et al Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6076.